Old Web
English
Sign In
Acemap
>
authorDetail
>
Daniel Reyner
Daniel Reyner
AstraZeneca
Dapagliflozin
Medicine
Endocrinology
Type 2 diabetes
Diabetes mellitus
5
Papers
142
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (5)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Renal haemodynamic response to sodium-glucose cotransporter-2 inhibition does not depend on protein intake: An analysis of three randomized controlled trials.
2021
Diabetes, Obesity and Metabolism
Annemarie B van der Aart-van der Beek
David Z.I. Cherney
Gozewijn D. Laverman
Bergur V. Stefansson
Daniël H. van Raalte
Klaas Hoogenberg
Daniel Reyner
Qiang Li
Gian Luca Di Tanna
Peter J. Greasley
Hiddo J.L. Heerspink
Show All
Source
Cite
Save
Citations (2)
Durability of Glycemic Control with Dapagliflozin, an SGLT2 Inhibitor, Compared with Saxagliptin, a DPP4 Inhibitor, in Patients with Inadequately Controlled Type 2 Diabetes
2019
Diabetes, Obesity and Metabolism
Clifford J. Bailey
Stefano Del Prato
Cheryl Wei
Daniel Reyner
Gabriela Luporini Saraiva
Show All
Source
Cite
Save
Citations (5)
Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial
2019
The Lancet Diabetes & Endocrinology
Carol A. Pollock
Bergur V. Stefansson
Daniel Reyner
Peter Rossing
C. David Sjöström
David C. Wheeler
Anna Maria Langkilde
Hiddo J. Lambers-Heerspink
Show All
Source
Cite
Save
Citations (65)
Wirksamkeit und Verträglichkeit von Dapagliflozin bei Patienten mit Typ-2-Diabetes und moderater Niereninsuffizienz (Chronische Nierenerkrankung Stadium 3A): Die DERIVE-Studie
2019
Paola Fioretto
S. Del Prato
Ronald Goldenberg
Francesco Giorgino
Daniel Reyner
Anna Maria Langkilde
D. Sjostrom
Peter Sartipy
M Kittel
Show All
Source
Cite
Save
Citations (0)
Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study
2018
Diabetes, Obesity and Metabolism
Paola Fioretto
Stefano Del Prato
John B. Buse
Ronald Goldenberg
Francesco Giorgino
Daniel Reyner
Anna Maria Langkilde
C. David Sjöström
Peter Sartipy
Show All
Source
Cite
Save
Citations (70)
1